Increased frequency of expression of elevated dihydrofolate reductasc in T-cell versus B-precursor acute lymphoblastic leukemia in children

Blood

Volumn 90, Issue 2, 1997, Pages 578-589

  Matherly, Larry H ^a   Taub, Jeffrey W ^b   Wong, So C ^b   Simpson, Pippa M ^b   Ekizian, Rachenii ^b   Buck, Steve ^b   Williamson, Michael ^b   Amylon, Michael ^b   Pullen, Jeannette ^b   Camitta, Bruce ^b   Ravindranath, Y ^b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B LYMPHOCYTE; CAUCASIAN; CHILD; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; NEGRO; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; T LYMPHOCYTE;

EID: 0030835804     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.2.578.578_578_589     Document Type: Article

References (45)

1. Poplack DG: Acute lymphoblastic leukemia, in Pizza PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology. Philadelphia, PA, Lippincott, 1993
2. Pui CH, Behm FG, Crist WM: Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82:343, 1993
3. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R: Uniform apporach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14:18, 1996
4. Borowitz MJ, Carroll AJ, Shuster JJ, Look AT, Behm FG, Pullen DJ, Land VJ, Steuber P, Crist WM: Use of clinical and laboratory features to define prognostic subgroups in B-precursor acute lymphoblastic leukemia: Experience of the Pediatric Oncology Group. Recent Results Cancer Res 131:257, 1993
5. Shuster JJ, Falletta JM, Pullen J, Crist WM, Humphrey B, Dowell BL, Wharam MD, Borowitz M: Prognostic factors in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 75:166, 1990
6. Ravindranath Y, Kaplan J, Zuelzer WW: Significance of mediastinal mass in acute lymphoblastic leukemia. Pediatrics 55:889, 1975
7. Pui CH, Crist WM: Biology and treatment of acute lymphoblastic leukemia. J Pediatr 124:491, 1994
8. Matherly LH, Taub JW: Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leuk Lymphoma 21:359, 1996
9. Barredo JC, Synold TW, Laver J, Relling MV, Pui C-H, Priest DG, Evans WE: Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84:564, 1994
10. Goker E, Lin JT, Trippett T, Elisseyeff Y, Tong WP, Niedzwiecki D, Tan C, Steinherz P, Schweitzer BI, Bertino JR: Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 7:1000, 1993
11. Goker E, Waltham M, Kheradpour A, Tippett T, Mazumdar M, Elisseyeff Y, Schnieders B, Steinhertz P, Tan C, Berman E, Bertino JR: Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 86:677, 1995
12. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, Evans WE: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J Clin Invest 97:73, 1996
13. Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, Gimotty P, Buck S, Wright JE, Rosowsky A: Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphocytic leukemia. Blood 85:500, 1995
14. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, Crist WM, Pui CH, Evans WE: Blast cell methotrexate polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94:1996, 1994
15. Trippett T, Schlemmer S, Elisseyeff Y, Goker E, Wachter M, Steinherz P, Tan C, Berman E, Wright JE, Rosowsky A, Schwitzer B, Bertino JR: Defective transport as a mechanism of acquired resistance to methtorexate in patients with acute lymphocytic leukemia. Blood 80:1158, 1992
16. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, Witte A, Beaulieu D: Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis. Blood 76:44, 1990
17. Whitehead VM, Vuchich MJ, Lauer SJ, Mahoney D, Carroll AJ, Shuster JJ, Esseltine DW, Payment C, Look AT, Akabutu J, Bowen T, Taylor LD, Camitta B, Pullen DJ: Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 80:1316, 1992
18. Fry DW, Yalowich JC, Goldman ID: Rapid formation of polyglutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cells. J Biol Chem 257:1890, 1982
19. Rosowsky A, Wright JE, Shapiro H, Beardsley P, Lazarus H: A new fluorescent dihydrofolate reductase probe for studies of methotrexate resistance. J Biol Chem 257:14162, 1982
20. Shapiro HM: Practical flow cytometry (ed 2). New York, NY, Wiley-Liss, 1988
21. Altman DG: Practical Statistics for Medical Research. London, UK, Chapman and Hall, 1991
22. Chiogna M, Spiegelhalter DJ, Franklin RCG, Bull K: An empirical comparison of expert-derived and data-derived classification trees. Stat Med 15:157, 1996
23. Venables WN, Ripley BD: Modern Applied Statistics With S-Plus. New York, NY, Springer Verlag, 1994
24. Campbell MJ, Machin D: Medical Statistics: A Common Sense Approach (ed 2). Chichester, UK, John Wiley and Sons, 1993
25. Kamen BA, Nylen PA, Whitehead VM, Abelson HT, Dolnick BJ, Peterson DW: Lack of dihyrofolate reductase in human tumor and leukemia cellls in vivo. Cancer Drug Delivery 2:133, 1985
26. Novakovic B: U.S. childhood cancer survival, 1973-1987. Med Pediatr Oncol 23:480, 1994
27. Pui CH, Boyett JM, Hancock ML, Pratt CB, Meyer WH, Crist WM: Outcome of treatment for childhood cancer in black as compared with white children. JAMA 273:633, 1995
28. Kalwinsky DK, Rivera G, Dahl GV, Roberson P, George S, Murphy S, Simone JV: Variation by race in presenting clinical and biologic features of childhood acute lymphoblastic leukemia: Implications for treatment outcome. Leuk Res 9:817, 1985
29. Look A, Melvin S, Williams D., Brodeur G, Dahl G, Kalwinsky D, Murphy S, Mauer A: Aneupoloidy and percentage of S-phase cells as determined by flow cytometry correlate with cell phenotype in childhood acute leukemia. Blood 60:959, 1982
30. Scarffe JH, Hann IM, Evans DIK, Morris Jones P, Palmner MK, Lilleyman JS, Crowther D: Relationship between the pretreatment proliferative activity of marrow blast cells and prognosis of acute lymphoblastic leukemia of childhood. Br J Cancer 41:764, 1980
31. Suarez C, Miller DR, Steinherz PG, Melamed MM, Andreef M: DNA and RNA determination in 111 cases of childhood acute lymphoblastic leukaemia (ALL) by flow cytometry: Correlation of FAB classification with DNA stemline and proliferation. Br J Haematol 60:677, 1985
32. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Brodsky I, Haines DS: High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 87:1155, 1996
33. Yeargin J, Cheng J, Yu AL, Gjerset R, Bogart M, Haas M: p53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T-cell acute lymphoblastic leukemia cell lines. J Clin Invest 91:2111, 1993
34. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar MJ: The human MDM-2 oncogene is overexpressed in leukemias. Blood 82:2617, 1993
35. INK4B) display freqent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood 84:4038, 1994
36. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S, Hayashi Y: Homozygous deletions of p16/ MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 86:1269, 1995
37. INK4A and p18, in childhood T-cell lineage acute lymphoblastic leukemias. Leukemia 10:255, 1996
38. Nakao M, Yokota S, Kaneko H, Seriu T, Koizumi S, Takaue Y, Fujimoto T, Misawa S: Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: Mutations of CDKN2 are observed preferentially in T-lineage. Leukemia 10:249, 1996
39. Hsiao MH, Yu AL, Yeargin J, Ku D, Haas M: Nonheriditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 83:2922, 1994
40. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84:3105, 1994
41. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler HP: Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82:3163, 1993
42. Wada M, Asada M, Nakazawa S, Itoh H, Kobayaski Y, Inoue T, Fukumuro K, Chan LC, Sugita K, Hanada R, Akuta N, Koboyaski N, Mizutani S: Clonal expansion of p53 mutant cells in leukema progression in vitro. Leukemia 8:53, 1994
43. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Weite K, Gadner H, Riehm H: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM86. Blood 84:3122, 1994
44. Patte C, Kalifa C, Flamant F, Hartmann O, Brugieres L, Valteau-Couanet D, Bayle C, Caillaud JM, Lemerle J: Results of the LMT81 protocol, a modified LSA2-L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 20:105, 1992
45. Karz JA, Shuster JJ, Ravindranath Y, Jacaruno D, Berand C, Amylon MD: Secondary acute myleogenous leukemia (AML) following intensive treatment for childhood T-cell acute lymphoblastic leukemia (T-ALL) and advanced stage lymphoblastic lymphoma (LL) treated with teniposide (VM-26): A Pediatric Oncology Group (POG) study. Proc Am Soc Clin Oncol 14:344, 1995